| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8202537 | NEXTWAVE PHARMS | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(3 years from now) | |
| US8287903 | NEXTWAVE PHARMS | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(7 years from now) | |
| US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11633389 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
Quillichew Er is owned by Nextwave Pharms.
Quillichew Er contains Methylphenidate Hydrochloride.
Quillichew Er has a total of 10 drug patents out of which 0 drug patents have expired.
Quillichew Er was authorised for market use on 04 December, 2015.
Quillichew Er is available in tablet, extended release, chewable;oral dosage forms.
Quillichew Er can be used as a method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1, a method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed, a method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed.
The generics of Quillichew Er are possible to be released after 14 August, 2033.
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet accor...
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
QUILLICHEW ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic